文献速递甲状腺与颈部外科围术期管理与 ERAS

以患者为中心决策实现内分泌手术后无阿片类药物:一项随机临床试验

Patient-Centered Decision-making for Postoperative Narcotic-Free Endocrine Surgery: A Randomized Clinical Trial.
PubMed 文献 · JAMA Surg · 2021-11-10

该随机临床试验在单个三级转诊中心纳入102例门诊甲状腺和甲状旁腺手术患者,比较术后阿片类药物选择加入策略(POINT)与常规阿片处方。结果显示POINT组阿片处方量减少且未增加术后疼痛,选择加入策略可减少阿片处方而不增加疼痛。

要点

  • POINT策略将术后阿片处方限于主动选择加入的患者,可减少阿片处方量。
  • POINT组与对照组术后峰值疼痛评分中位数均为6,差异无统计学意义。
  • 有阿片使用史的患者更可能选择加入并消耗阿片类药物。

核心结论

  • 在甲状腺和甲状旁腺手术后,选择加入策略减少阿片处方而不增加术后疼痛。

主要发现

  • 对照组阿片处方总量550片,POINT组230片,POINT组中23例(47.9%)选择加入阿片处方。

关键数值与推荐

  • 非劣效性定义为11点数字评分量表(0-10)上差异小于2。
  • POINT组患者接受围手术期疼痛管理咨询,仅在患者要求时开具阿片处方。

临床怎么用

  • 对于门诊甲状腺和甲状旁腺手术患者,可采用选择加入策略限制术后阿片处方,以减少阿片消耗和滥用风险而不增加疼痛。

局限性

  • 研究为单中心随机临床试验,样本量较小,最终分析102例患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Historically, opioid pain medications have been overprescribed following thyroid and parathyroid surgery. Many narcotic prescriptions are incompletely consumed, creating waste and opportunities for abuse. OBJECTIVE: To determine whether limiting opioid prescriptions after outpatient thyroid and parathyroid surgery to patients who opt in to narcotic treatment reduces opioid consumption without increasing postoperative pain compared with usual care (routine narcotic prescriptions). DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial of Postoperative Opt-In Narcotic Treatment (POINT) or routine narcotic prescription (control) was conducted at a single tertiary referral center from June 1 to December 30, 2020. A total of 180 adults undergoing ambulatory cervical endocrine surgery, excluding patients currently receiving opioids, were assessed for eligibility. POINT patients received perioperative pain management counseling and were prescribed opioids only on patient request. Patients reported pain scores (0-10) and medication use through 7 daily postoperative surveys. Logistic regression was used to determine factors associated with opioid consumption. INTERVENTIONS: Patients in the POINT group were able to opt in or out of receiving prescriptions for opioid pain medication on discharge. Control patients received routine opioid prescriptions on discharge. MAIN OUTCOMES AND MEASURES: Daily peak pain score through postoperative day 7 was the primary outcome. Noninferiority was defined as a difference less than 2 on an 11-point numeric rating scale from 0 to 10. Analysis was conducted on the evaluable population. RESULTS: Of the 180 patients assessed for eligibility, the final study cohort comprised 102 patients: 48 randomized to POINT and 54 to control. Of these, 79 patients (77.5%) were women and median age was 52 (interquartile range, 43-62) years. A total of 550 opioid tablets were prescribed to the control group, and 230 tablets were prescribed to the POINT group, in which 23 patients (47.9%) opted in for an opioid prescription. None who opted out subsequently required rescue opioids. In the first postoperative week, 17 POINT patients (35.4% of survey responders in the POINT group) reported consuming opioids compared with 27 (50.0%) control patients (P = .16). Median peak outpatient pain scores were 6 (interquartile range, 4-8) in the control group vs 6 (interquartile range, 5-7) in the POINT group (P = .71). In multivariate analysis, patients with a history of narcotic use were 7.5 times more likely to opt in (95% CI, 1.61-50.11; P = .02) and 4.8 times more likely to consume opioids (95% CI, 1.04-1.52; P = .01). Higher body mass index (odds ratio, 1.11; 95% CI, 1.01-1.23; P = .03) and highest inpatient postoperative pain score (odds ratio, 1.24; 95% CI, 1.04-1.52; P = .02) were also associated with opioid consumption. CONCLUSIONS AND RELEVANCE: In this trial, an opt-in strategy for postoperative narcotics reduced opioid prescription without increasing pain after cervical endocrine surgery. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04710069.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Zhu CY, Schumm MA, Hu TX, et al. Patient-Centered Decision-making for Postoperative Narcotic-Free Endocrine Surgery: A Randomized Clinical Trial. JAMA Surg. 2021. PMID: 34495283. doi:10.1001/jamasurg.2021.4287

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。